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A B S T R A C T
Diabetic foot ulcer is a serious complication of diabetes, resulting from peripheral neuropathy, macrovascular
and microvascular disease, impaired angiogenesis and chronic inflammation. Epiphyllum oxypetalum leaves have
been proven to be efficacious in incision wound healing. This project aimed to evaluate the wound healing
properties of topical application of Epiphyllum oxypetalum leaves in diabetic mice. Diabetes was induced using
streptozotocin. Wound healing activity was assessed by incision model. A total of 40 mice were used in this
project, divided into four groups: WE10 and WE20 groups were treated topically with 10% and 20% Epiphyllum
oxypetalum leaf extract ointment, respectively, while the diabetic control and non-diabetic groups were treated
topically with the ointment base. The results showed significant wound healing progress in mice treated with
Epiphyllum oxypetalum extract ointment, as assessed by wound contraction, number of macrophages and fibro-
blast count. In conclusion, topical application of 96% ethanol extract of Epiphyllum oxypetalum leaves could
accelerate the wound healing time in diabetic mice, where the best activity was shown by 20% Epiphyllum
oxypetalum extract.
1. Introduction
People diagnosed with diabetes have a 25% chance of developing a
diabetic foot ulcer (DFU). Patients with DFU are more likely to have
early death, myocardial infarction and fatal stroke than those without
DFU. This disorder is often associated with diabetic neuropathy, per-
ipheral vascular disease, and irregular cellular and cytokine activity
[1–4]. Healthcare costs associated with diabetic ulcers and amputations
contribute significantly to the economic problem of diabetic patients
[5], and the recurrence rate for foot ulcers is more than 50% after 3
years [6].
Some of the important reasons for impaired diabetic wound healing
include abnormal keratinocyte and fibroblast migration, proliferation,
differentiation and apoptosis, abnormal macrophage polarisation, de-
creased vascularisation and prolonged expression of TNF- α [7]. The
role of macrophages in wound healing includes phagocytosing debris
and producing vascular endothelial growth factor, which controls tissue
repair and induces the formation of lymphatic and blood vessels. In-
terference in the activation of these macrophages and depletion of the
inflammatory mediator in diabetic wounds could delay the in-
flammatory process, which is the main cause of wound healing disorder
in diabetic patient [8,9]. Furthermore, the delay in inflammatory re-
sponse could lead to infection and wound aggravation [10].
Early intervention with DFU would reduce the number of patients
progressing into further complications, infection and necrosis, and thus
reduce the number of major amputations in diabetic patients [11].
Surgical debridement is one of the standard treatments for handling
diabetic wounds, but this therapy requires substantial funds and is also
very painful [12]. Therefore, early treatment using natural materials
would be beneficial for patients. Several plants have been studied for
their activity on the diabetic wound healing process, such as Syzygium
mundagam, Blechnum orientale Linn., Centella asiatica, Lepidium meyenii,
Carthamus tinctorius and Avena sativa [13–18]. Epiphyllum oxypetalum
(DC.) Haw., with the common name Night Blooming Cereus or known
in Indonesia as Wijaya Kusuma [19], has been used by the citizens of
Indonesia to heal general incision wounds. Research has shown that
Wijaya Kusuma has antimicrobial potential against Staphylococcus
aureus, a common bacteria that delays wound healing [20,21]. In ad-
dition, Wijaya Kusuma leaves have been proven to be efficacious as an
anti-inflammatory and antioxidant [22,23]. Other natural products,
such as Radix Astragali and Radix Rehmanniae herbs, have been stu-
died to enhance diabetic wound healing through their anti-in-
flammatory properties [24]. Thus, Wijaya Kusuma leaves extract could
also have potential as a diabetic wound healing drug. No studies have
been done regarding this, highlighting the need for this current re-
search. This study aimed to determine Wijaya Kusuma efficacy in the
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wound healing process in diabetic mice.
2. Materials and methods
2.1. Wijaya Kusuma extraction and ointment preparation
The leaves of Wijaya Kusuma used in this research were obtained
from Balai Penelitian Tanaman Rempah dan Obat (Balitro) Bogor,
Indonesia. Based on the results of determination in the Herbarium
Bogoriense Botanical Field Centre Biological Research – LIPI Cibinong,
the plant species is Epiphyllum oxipetalum (DC) Haw. from the family
Cactaceae. Three kilograms of fresh Wijaya Kusuma leaves were used in
the extraction process. The leaves were dried and mashed into coarse
powder form, then extracted by maceration method using 96% ethanol.
The extract was then concentrated using a vacuum rotary evaporator
at± 50 °C. The Wijaya Kusuma extract ointment was prepared using
sterilised Vaseline flavum base.
2.2. Animals and experimental design
A total of 40 12-week-old male Swiss Webster mice weighing be-
tween 25 and 30 g were used in this study. The study protocol was
approved by the Research Ethics Commission, Faculty of Medicine,
University of Indonesia by applying the principles of replacement, re-
duction and refinement (the 3Rs) with approval under ethics number
510/UN2.F1/ETIK/2017. The mice were allowed to acclimatise for 7
days prior to the experiment. The mice were kept under standard la-
boratory conditions (22–25 °C and a 12-h light/dark cycle) and fed with
standard pellets diet and water ad libitum. After overnight fasting, all
the mice were induced with a single intraperitoneal (i.p.) injection of
60mg/kg body weight (BW) streptozotocin (STZ) in 0.01M citrate
buffer (pH 4.5), except for the non-diabetic group [15,25].
The animals were divided into four experimental groups with ten
animals in each group, consisting of:
WE10: treated topically with 10% Wijaya Kusuma extract ointment
WE20: treated topically with 20% Wijaya Kusuma extract ointment
DC: diabetic control group, treated topically with the ointment base
N-DC: non-diabetic group, treated topically with the ointment base.
2.3. Excisional wound preparation and macroscopic examination
The mice in each group were wounded 5 days after STZ injection. In
this research, STZ induction increased the blood glucose concentration
in the animals to ≥ 200mg/dl, which was considered as hypergly-
caemic. Briefly, the mice were anesthetised with a single i.p. injection
of ketamine (2mg/25 g of BW). The hair on the back of each mouse was
shaved and wiped with 70% ethanol. A full-thickness wound (1 cm
diameter) was made on the back of each mouse by excising the un-
derlying panniculus carnosus of the skin [26]. A day after being
wounded, the WE10 and WE20 groups were treated topically once daily
with Wijaya Kusuma extract ointment, while the diabetic control (DC)
and non-diabetic (N-DC) groups were treated topically with the oint-
ment base for 14 days. Skin biopsy specimens were obtained from the
animals (2 mice of each group) 3, 7, 10 and 14 days post-wounding. An
area that included the scab, the complete epithelial and dermal com-
partments of the wound margins, the granulation tissue, parts of the
adjacent muscle and subcutaneous fat tissue was excised from each
individual wound at each time point. Each wound site was digitally
photographed every day. The photos were then used to determine the
wound area using ImageJ software (open source ImageJ software
available at https://imagej.nih.gov/ij/) [27]. Wound area was used to
calculate the percentage of wound contraction.
=
−Initial wound area wound area day n
initial wound area
WoundContraction (%) 100%
2.4. Histopathological studies
A specimen sample was isolated from each group of mice on day 3,
7, 10 and 14 days after wounding for histopathological examination.
The skin specimens were fixed immediately in 10% (v/v) neutral buf-
fered formalin. Each specimen was embedded in a paraffin block and
thin sections (5 μm) were prepared and stained with haematoxylin and
eosin for general morphological observations [28].
2.5. Quantification of macrophages and fibroblasts
Histologic observation was done in 10-images view with 400×
objective magnification.
2.6. Blood glucose analysis
The blood glucose levels were determined using a glucometer (Easy
Touch).
2.7. Statistical analysis
The data were first tested for normality and for variance homo-
geneity prior to any further statistical analyses. The data were normally
distributed and were expressed as the mean ± SEM (standard error of
the mean). The differences between the groups were analysed by one-
way analysis of variance (one-way ANOVA) (for more than two groups)
followed by Tukey’s post-test.
3. Results
The wound healing observation results showed that both groups
treated with Wijaya Kusuma extract at concentrations of 10% (WE10)
and 20% (WE20) presented a rapid decline of wound area, while the
diabetic control (DC) group tended to decrease more slowly in spite of
the greater wound area of the WE10 and WE20 groups in the early days
after the incision (Fig. 1.). Mice treated with WE10 and WE20 showed a
significant (p < 0.05) wound contraction compared to the DC group
starting from day 3 of the wound healing process (Table 1.). Never-
theless, from day 7, only the WE20 group showed activity comparable
(p > 0.05) to that of the non-diabetic control (N-DC) group (Table 1.),
implying the treatment capability in accelerating the wound healing
was similar to the normal process, despite the high glucose condition.
Table 2. shows that the groups treated with WE10 and WE20 ex-
hibited more macrophages than DC on day 3. In the DC group, the
number of macrophages was lower in the early wound phase (day 3)
but increased significantly on day 7. The high number of macrophages
on day 7 indicated that the inflammation continues to a chronic con-
dition, which is a common diabetic problem [8]. In the meantime, on
day 7 the WE20 group showed a better result with a lower number of
macrophages compared to the WE10 group, and comparable to the N-
DC group.
Table 3. shows that the peak number of fibroblasts was seen on day
Fig. 1. Wound areas for mice: Wijaya Kusuma extract (WE), diabetic control
(DC) and non-diabetic control (N-DC) groups.
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10, with the highest number of fibroblasts observed in the N-DC group,
followed by the WE20 and WE10 groups. High numbers of fibroblasts
were observed in the WE20 and WE10 groups started from day 7, which
confirmed the beginning of the proliferation phase, and the fibroblast
numbers decreased on day 14 where this phase ended.
Fig. 2A.c shows that were more macrophages on day 7 in the DC
group compared to the WE10, WE20 and N-DC groups (Fig. 2A. a, b and
d). Fig. 2B shows a high fibroblast density in all groups except for the
DC group (Fig. 2.B.c), which is beneficial for the proliferation phase of
the wound healing process.
4. Discussion
The diabetic wound could not progress through the normal healing
process, which leads to a prolonged inflammation phase and infection
[29]. In order to prevent delayed wound healing in diabetics, early
treatment should be applied, including the use of plant extracts. This
work showed that topical application of both 10% and 20% Wijaya
Kusuma extract ointment could decrease wound healing time in the
diabetic condition. The healing activity of Wijaya Kusuma was seen to
start from day 3 onwards, which was shown by the higher wound
contraction, incomparable to the DC group (Table 1). This finding
showed that Wijaya Kusuma leaf extract could heal diabetic wounds
faster than Lepidium meyenii (black maca) root extract ointment, which
showed a significant wound contraction starting on day 10 [15]. In
addition, wound contraction rate with Wijaya Kusuma showed dose-
dependent activity.
In the wound healing process, the first to third days are critical for
the early inflammatory stage, in which macrophages play an important
role in preventing infection in the wound area [30]. Depletion of
macrophages during this phase results in a significant delay to wound
repair, which is common in diabetics [7]. In addition, macrophages can
generate growth factors that are useful for starting the proliferative
phase [31]. On day 3, in the diabetic state, the number of macrophages
is less than that in normal wounds, which interferes with the early in-
flammatory process. This was confirmed by the DC group, where the
macrophage number was significantly lower than that of the N-DC
group by 37.82%. On the other hand, mice treated with WE10 and
WE20 exhibited a normal inflammatory phase, which was confirmed by
a similar number of macrophages with N-DC. The macrophage numbers
of the WE10 and WE20 groups on day 3 were higher than those in the
DC group by 26.04 and 33.47%, respectively. Dysfunctional macro-
phages have been proven to increase apoptotic cell burden at the
wound site, thus prolonging inflammation and obscuring wound
healing [9].
The DC group showed less macrophages in the early wound phase
but this increased significantly later on day 7. Consequently, the longer
continuous inflammation time caused chronic inflammation of the
Table 1
Wound contraction percentage.
Day Wound contraction (%)
WE10 WE20 DC N-DC
3 2.22a 2.85a 1.04b 2.98a
7 11.56ab 13.57a 9.57b 14.16a
10 25.03ab 30.16a 15.48b 31.67a
14 53.50ab 68.86a 23.93b 70.05a
Wijaya Kusuma Extract (WE), diabetic control (DC) and non-diabetic control
(N-DC).
a Significantly different from DC at the 0.05 level.
b Significantly different from N-DC at the 0.05 level.
Table 2
Total macrophages numbers.
Groups Day 3 Day 7
WE10 68.15 ±3.572a 67.10 ± 2.208b
WE20 75.75 ±4.335a 57.15 ± 3.307a
DC 50.40 ±3.408b 74.25 ± 3.313b
N-DC 81.05 ±3.631a 54.50 ± 2.811a
Wijaya Kusuma extract (WE), diabetic control (DC) and non-diabetic control
(N-DC).
a Significantly different from DC at the 0.05 level.
b Significantly different from N-DC at the 0.05 level.
Table 3
Total fibroblast numbers.
Groups Day 7 Day 10 Day 14
WE10 31.10 ± 7.656b 38.80 ±8.256a 24.40 ± 8.444a
WE20 33.05 ± 9.506a 40.70 ±12.12a 23.10 ± 10.82a
DC 22.55 ± 8.690b 29.85 ±7.849b 32.60 ± 7.096b
N-DC 35.15 ± 8.652a 44.25 ±11.76a 21.60 ± 10.66a
Wijaya Kusuma extract (WE), diabetic control (DC) and non-diabetic control
(N-DC).
a Significantly different from DC at the 0.05 level.
b Significantly different from N-DC at the 0.05 level.
Fig. 2. Histological changes in the wounds on day 7 (A) and day 10 (B) (haematoxylin and eosin staining; 400× magnification). a) Diabetic group treated with 10%
WE (WE10); b) diabetic group treated with 20% WE (WE20); c) Diabetic Control (DC); and d) Non-Diabetic control (N-DC). Macrophage (↑), Fibroblast (↑).
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wound. In contrast, the WE20 group showed a significantly lower
number of macrophages compared to the DC group on day 7. This
confirmed the activity of WE20 in accelerating the healing of diabetic
wounds in the inflammatory phase.
Another important parameter of wound healing progression is fi-
broblasts. This component of skin tissue is the primary source of ex-
tracellular matrix proteins such as collagen and fibronectin. In a dia-
betic wound, there is a decrease in migration and proliferation of
fibroblasts [7]. An increase in the local inflammatory response is at-
tributed to the lack of growth factor production, which is important for
fibroblast activation [32]. In the normal wound healing process, the
proliferation phase would start between days 5 and 7, which is in-
dicated by the increase in the number of fibroblasts [30].
Fig. 3. illustrates the changes in the fibroblast numbers in the tested
groups. Wounds treated with WE10 and WE20 showed a similar trend
to the N-DC group, where the fibroblast number increased from day 7 to
reach a peak on day 10. The higher the fibroblast number at the peak,
the better the healing process occurs in the proliferation phase [32].
The highest peak is seen in the N-DC group, followed by WE20 and
WE10, sequentially. The number of fibroblasts for these groups then fall
rapidly on day 14, showing that the proliferation phase was almost
completed, and continued to the remodelling phase, the final phase of
the wound healing process. Meanwhile, the DC group showed late ac-
tivation of fibroblasts, despite the steady incline. It is possible that
diabetic wound treatment with WE might increase the activity of in-
flammatory cells, leading to the proper inflammation response and
accelerating the proliferation phase in wound healing process. This
acquaintance possibly underlies the role of this plant in elevating the
fibroblast numbers at the wound site.
Phytochemicals examination of WE showed that the extract contains
alkaloid, flavonoid, tannin, saponin and steroid. Several studies have
shown flavonoid mechanism in wound healing by modulating the ex-
pression of cytokines and nitric oxide in the Inflammation phase [33].
Recruitment of macrophages by Epiphyllum oxypetalum was suspected
due to these mechanisms. The similar mechanisms could also be ex-
pected to occur in wounds in humans [34].
Lower macrophage density was obviously seen in the WE10 and
WE20 groups on day 7 compared to that in the DC group (Fig. 2A). The
histopathological results in Fig. 2B. b demonstrated better regeneration
in the skin wound for the WE20 group. The presence of numerous fi-
broblasts in the tissue in the WE groups, particularly at 20% con-
centration, indicates that the wound healing process reached the pro-
liferation phase on day 7 and continued to day 10. A similar
observation was made in an analogue wound healing study using other
plants, such as Sida cordifolia Linn [35]. However, the methanolic ex-
tract of Sida cordifolia in hydrogel form exhibited 100% wound con-
traction at day 14, while in this research Wijaya Kusuma showed only
70% wound contraction. Wound healing in rats mostly occurs through
wound contractions. This mechanism also plays a major role in acute
and chronic wounds in humans. Failure on rapid contraction appears to
be a significant problem in diabetic ulcers [36]. However, infection, the
location of the ulcer, and foot deformities which are important factors
that influence the healing process in diabetic patients are not applied in
this diabetes wound model. Thus, in future research investigations
could be attempted with other types of preparations to improve the
effectiveness of Wijaya Kusuma extract in diabetic wounds.
5. Conclusion
The groups treated with 10% and 20% WE showed significant
wound healing compared to the DC group. The best activity was shown
by the WE20 group, which was comparable to that of the N-DC group.
From the results above, it can be concluded that topical application of
96% ethanol extract of Wijaya Kusuma (Epiphyllum oxypetalum (DC.)
Haw.) leaves could accelerate the wound healing process in diabetics.
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